Prognostic biomarkers of Amyotrophic Lateral Sclerosis (ALS): A s | 40707
Journal of Proteomics & Bioinformatics

Journal of Proteomics & Bioinformatics
Open Access

ISSN: 0974-276X

+44 1223 790975

Prognostic biomarkers of Amyotrophic Lateral Sclerosis (ALS): A step forward in the understanding of the disease

Joint Event on 9th World Biomarkers Congress & 20th International Conference on Pharmaceutical Biotechnology

December 07-09, 2017 | Madrid, Spain

Ana Cristina Calvo

University of Zaragoza, Spain

Scientific Tracks Abstracts: J Proteomics Bioinform

Abstract :

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of unknown origin that causes progressive muscle paralysis and motor neuron death. The need of reliable biomarkers of ALS that can be accurately monitoring along disease progression is an increasing field of research. In this sense, our main objective is to identify molecular biomarkers as key elements of the induced neurodegeneration in ALS. Previous studies in our research workgroup analysed the transcriptional expression of a group of genes, whose expression was found up and down-regulated significantly in a preliminary microarray study and in muscle biopsy samples from transgenic SOD1G93A mice, the best characterized murine model for the disease. In this study we identified five genes, Mef2c, Gsr, Col19a1, Calm1 and Snx10 as potential genetic biomarkers of longevity in this animal model. Next, we translated this study to ALS patient��?s samples to validate the potential nature of these biomarkers. Skeletal muscle biopsies and blood samples from sporadic and familial ALS patients were analyzed by real time PCR and Western blot to test the expression levels of fifteen genes and fourteen proteins. ROC curves, multinomial regression and timedependent Cox regression analysis were performed. COL19A1 gene and protein levels were identified as potential prognostic candidates in skeletal muscle samples from ALS patients. In addition, the same gene improved prognosis in blood samples from sporadic ALS patients. These findings provide an important first step towards the accurate prediction of potential biomarkers in ALS be the initial springboard to new clinical trials and promising therapeutic strategies.

Biography :

Ana Cristina Calvo has completed her PhD in 2003 from the Anatomy and Human Histology Department in the University of Zaragoza in Spain and Post-doctoral studies from the ALS Unit in the Hospital 12 October in Madrid (Spain) and from Faculty of Medicine in the Universidad Autónoma in Barcelona (Spain). She is an Associate Professor in Genetics and member of the Laboratory of Genetics and Biochemistry (LAGENBIO, IA2-IIS) in the Faculty of Veterinary Sciences in the University of Zaragoza (Spain). She has published 30 papers in reputed journals and participated as a coauthor in three licensed patents.